NANOBIOTIX Archives | Be Korea-savvy

Home / Posts tagged NANOBIOTIX

Nanobiotix Announces Publication of Phase III Soft Tissue Sarcoma Data for First-in-class NBTXR3 in the Lancet Oncology

Paris, France and Cambridge, Massachusetts, USA, Jul. 9 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the previously reported results from the Phase II/III Act.In.Sarc trial evaluating NBTXR3 in patients with advanced STS have been published online in The [...]

Nanobiotix Announces New Organizational Structure as the Company Enters its Next Stage After First European Market Approval

Paris, France and Cambridge, Massachusetts, USA, Jul. 1 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced organizational changes to align with strategic priorities post European market approval for Hensify® (NBTXR3). The changes aim to reinforce necessary competencies as strategic priorities [...]

Nanobiotix Appoints New Chief Medical Officer as the Company Evolves After Achievement of European Market Approval

Paris, France and Cambridge, Massachusetts, USA, Jun. 4 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced it has appointed Edwina Baskin-Bey, M.D. as its new CMO. Dr. Baskin-Bey brings over 18 years of oncology clinical development and basic science experience [...]

Nanobiotix Announces the Launch of Curadigm: a New Nanotechnology Platform for Healthcare

Paris, France and Cambridge, Massachusetts, USA, May 28 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced the launch of new subsidiary Curadigm, dedicated to redefining the therapeutic balance between bioavailability, toxicity, and efficacy across the pharmaceutical industry. The company will [...]

Nanobiotix Announces First Ever Radioenhancer to Receive European Market Approval

Paris, France, and Cambridge, Massachusetts (USA) Apr. 4 (Korea Bizwire) – NANOBIOTIX (Euronext : NANO – ISIN : FR0011341205), a clinical-stage nanomedicine company pioneering new approaches in the treatment of cancer, announced today that Hensify® (NBTXR3) has obtained a CE mark for the treatment of locally-advanced soft tissue sarcoma (“STS”). Hensify® is the brand name for NBTXR3 [...]

Combination of First-in-class NBTXR3, Radiotherapy, and Anti-PD-1 Immunotherapy Demonstrate Efficacy in Treating Resistant Pre-clinical in vivo Models of Lung Cancer

Paris, France; Cambridge, Massachusetts (USA); Apr. 2 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’) a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced preclinical data from studies currently being conducted under its collaborations with The University of Texas MD Anderson Cancer Center and the Weill Cornell [...]

Nanobiotix Announces its Clinical Registration Plan in Head and Neck Cancers for the United States Following FDA Feedback

Paris, France; Cambridge, Massachusetts (USA); Mar. 26 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the ‘‘Company’’), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the Company has clarity on its regulatory pathway in the treatment of Head and Neck cancers for first-in-class radioenhancer NBTXR3. The [...]

Nanobiotix 2018 Annual Results

Paris, France and Cambridge, Massachusetts, USA, Mar. 15 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited1 consolidated results for the fiscal year ended December 31, 2018: Major milestones achieved during the year: Positive Phase II/III [...]

Nanobiotix Receives €14 Million Through the Second Tranche Disbursement of Financing from the European Investment Bank

Paris, France and Cambridge, Massachusetts (USA), Mar. 4 (Korea Bizwire) – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced that the Company received €14 million through the second tranche disbursement of the non-dilutive loan from the European Investment Bank (EIB), which was originally [...]

Nanobiotix Plans to Conduct Registered Public Offering in the United States

Paris, France and Cambridge, Massachusetts, Jan. 16 (Korea Bizwire) – NANOBIOTIX SA (Euronext : NANO – ISIN : FR0011341205) announced today that it plans to conduct a registered public offering of its ordinary shares, including in the form of American Depositary Shares (ADSs) in the United States, and has confidentially submitted a draft registration statement [...]